Site Search Share Data Investor Relations Stock Information Share Data Listings in the U.S. and Europe QIAGEN’s common shares have been registered and traded in the United States since 1996, listing on the New York Stock Exchange effective January 10, 2018, after trading on NASDAQ markets since the initial public offering (IPO). The shares have traded in Germany on the Frankfurt Stock Exchange since 1997, and the Prime Standard segment since its launch in 2003. Dual listing on NYSE and the Frankfurt exchange offers advantages for QIAGEN, our shareholders and employees since global presence increases the potential market opportunity and enhances liquidity. Unlike American Depositary Receipts (ADRs), QIAGEN shares provide equal corporate rights for all shareholders and can be traded on either exchange, in U.S. dollars or euros. NYSE (effective January 10, 2018) / NASDAQ (until January 9, 2018) 2020 2019 2018 Year-end price $52.85 $33.80 $34.45 High $55.27 $43.16 $39.45 Low $32.97 $25.04 $30.78 Average daily trading volume (in million shares) 1.59 1.56 0.99 Frankfurt Stock Exchange (XETRA) 2020 2019 2018 Year-end price €42.45 €30.46 €29.68 High €46.95 €39.19 €34.05 Low €29.55 €22.54 €25.22 Average daily trading volume (in million shares) 0.91 0.60 0.53 Index Membership QIAGEN is a constituent in various European, U.S. and global stock indices, some of which serve as benchmarks or investment universes for mutual funds and exchange traded funds. QIAGEN ranks as one of the leading components by market capitalization in Germany’s TecDAX index, which includes the 30 largest German technology companies not in the benchmark DAX index. As of September 20, 2021, QIAGEN became a member of the DAX-40 index. QIAGEN also is a member of the Russell 3000 index, which measures performance of the 3,000 largest U.S. companies, and the Russell 1000, a subset with the largest 1,000 U.S. securities. QIAGEN shares also are included in other stock market indexes such as the MSCI Europe, EMU and EAFE indexes. Key share data 2020 2019 2018 Total equity (in $ thousands) 2,797,839 2,536,591 2,634,970 Issued shares (in thousands) 230,829 230,829 230,829 Outstanding shares at December 31 (in thousands) 227,985 227,752 225,509 Weighted-average number of common shares outstanding - basic (in thousands) 228,427 226,777 226,640 Weighted-average number of common shares outstanding - diluted (in thousands) 234,214 226,777 233,456 Year-end market capitalization (in $ million) 12,049 7,698 7,769 Year-end market capitalization (in € million) 9,678 6,937 6,693 Free Float (in %) 99.37 98.34 97.19 IR Contacts John Gilardi Vice President Head of Corporate Communications and Investor Relations Germany +49 2103 29 11711 U.S. +1 240 686 2222 The Netherlands +31 773 55 66 66 john.gilardi@qiagen.com Download VCARD Phoebe Loh Senior Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com Download VCARD Alexandra Koenig Investor Relations Coordinator +49 2103 29 11709 alexandra.koenig@qiagen.com Download VCARD Email Alerts Email Address SIGN UP Press Releases Events Presentations SEC-Filings End of Day Stock Quote Unsubscribe Follow Us linkedin open in new window facebook open in new window twitter open in new window youtube open in new window linkedin open in new window Contact Us call back mail BACK TO TOP This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Sample to Insight © QIAGEN 2013-21. All rights reserved Privacy Policy Trademarks & Disclaimers Accessibility Powered By Q4 Inc. 5.56.0.1 (opens in new window)